Dentatothalamic Projections Mediate Tremor Relief Across Deep Brain Stimulation Targets and Tremor Types
Objective: To investigate the neuroanatomical hotspots for the suppression of rest, postural and intention tremor in Parkinson’s Disease (PD) and Essential Tremor (ET) treated with…Slow-SPEED-US: Initiation of a Remote Exercise Trial in LRRK2 and GBA1 Carriers
Objective: To describe the launch of Slow-SPEED-US, presenting recruitment results and baseline characteristics of the enrolled subsample. Background: Slow-SPEED-US is part of a network of…Depression and Psychosis in military Veterans with Parkinson’s Disease (PD)
Objective: To compare the presence of co-morbid depression in groups of PD Veterans, with and without psychosis. Background: Depression and psychosis are important non motor…Axonal-demyelinating polyneuropathy after subcutaneous foslevodopa/foscarbidopa infusion – case report.
Objective: The aim of this report was to present a patient with Parkinson’s disease (PD) treated with continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) who developed axonal-demyelinating…Baicalein Attenuates Rotenone-Induced Neurodegeneration by Regulating BDNF/CREB/Akt Signaling in Parkinson’s Disease
Objective: To evaluate the therapeutic potential of baicalein and to investigate its underlying neuroprotective mechanism in a rotenone-induced mouse model of Parkinson’s disease. Background: Parkinson’s…Sublingual apomorphine for parkinsonian tremor: Post-hoc analysis of pivotal trial data
Objective: We explored tremor outcomes associated with apomorphine sublingual film (SL‑APO) in patients with a tremor‑dominant PD phenotype. Background: Tremor is a common and disabling…Analyzing the classification of 767 GBA1 variants to guide GBA1 PD risk prediction
Objective: To assess the consistency of GBA1 variant classification across large Parkinson’s disease (PD) and Gaucher disease (GD) cohorts and determine how variant-specific biochemical data…AI-based Progression and Medication Response Prediction in Parkinson’s Disease: the AI-PMP Study Protocol
Objective: To evaluate proof-of-concept performance of two artificial intelligence (AI) multivariable models predicting (1) motor disease progression and (2) treatment-related side effects over 12 months…Clinical and Biomarker Trajectories in GBA1 Non-Manifesting Carriers With and Without α-Synuclein Seed Amplification Positivity
Objective: To characterize clinical and biomarker features of GBA1-NMC and evaluate whether CSF-αSynSAA status is associated with longitudinal clinical progression and phenoconversion. Background: Pathogenic variants…Retrospective Evaluation of microRNA-7-5p and Neuron-Derived α-Synuclein in Prodromal Parkinson’s Disease as Phenoconversion Biomarkers
Objective: To determine if combining microRNA-7-5p (miR-7-5p) and neuron-derived extracellular vesicle (NDEV) α-synuclein (α-syn) would enrich prodromal Parkinson's disease (PD) subjects for those more likely to phenoconvert. Background: Studies have found blood…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 553
- Next Page »